【2h】

Prognostic factors in CLL

机译:CLL的预后因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, as some patients progress rapidly toward the more advanced studies, whereas others survive for a long period without the need for treatment. This heterogeneity of clinical course was somehow unexplained until studies on the CLL cell features disclosed that the CLL clones were heterogeneous and were characterized by different phenotypic and genotypic features in the different patients. On the basis of these observations, it was determined in retrospective studies that clones characterized by unmutated IGHV genes, and/or CD38 and/or ZAP-70 expression conferred a more severe prognosis to the CLL patients. Here, we present data on prospective studies carried out on Binet A-stage patients, in whom the markers were determined at diagnosis and their predictive value was assessed in comparison with chromosomal abnormalities and gene expression or micro RNA profiles. In addition, hypothesis on the potential pathogenetic role of these markers will be presented.
机译:慢性淋巴细胞性白血病(CLL)是一种临床上的异质性疾病,因为有些患者可以迅速进入更高级的研究,而其他患者则可以长期生存而无需治疗。直到对CLL细胞特征的研究表明CLL克隆是异质的并且在不同患者中具有不同的表型和基因型特征后,临床过程的这种异质性才能以某种方式无法解释。基于这些观察,在回顾性研究中确定以未突变的IGHV基因和/或CD38和/或ZAP-70表达为特征的克隆赋予CLL患者更严重的预后。在这里,我们介绍了对Binet A期患者进行的前瞻性研究数据,这些患者在诊断时确定了标志物,并与染色体异常和基因表达或微RNA谱进行了比较,评估了其预测价值。另外,将提出关于这些标记物潜在致病作用的假设。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号